Chengdu Hyperway Pharmaceuticals Co., Ltd. ("Hyperway") announces that it has successfully received the angel + round financing of tens of millions of yuan. This round of financing is led by Huaige Capital, a domestic venture capital organization dedicated to the health care sector. This is the first time for Hyperway to obtain a professional investment in the pharmaceutical sector after it acquired angel round financing of tens of millions of yuan in 2019. This marks the R & D strength and  operation strategy of Hyperway have been well recognized in the field of pharmaceuticals. Its stock value has increased significantly in the short term. Due to the tight domestic and foreign capital and severe financing situation caused by the current global outbreak of COVID-19, many enterprises face shortage or break in the money chain. Favored by investment institutions such as Huaige Capital under such circumstances, Hyperway shows its great development strength.

New dynamics in R & D

Hyperway is a biopharmaceutical company focusing on innovative drug development. In order to ensure its long-term vitality, Hyperway has formulated its short- and medium-term development strategy. In its early stage, it implemented a two-wheel drive strategy of "guiding R&D of generic drugs and fine chemicals with innovative drugs, and feeding R&D of innovative drugs with the business of generic drugs and fine chemicals ". At present, a number of high-value-added fine chemical product projects have brought certain sales revenue to Hyperway, and a joint generic drug development project signed by Hyperway with its important partners has entered the stage of pilot scale production.

In the development of innovative drugs, Hyperway has a total of 9 R & D pipelines covering tumor, central nervous system, autoimmune system, pain, depression and other hot areas, and it has achieved exciting results in all such areas. One of the innovative drug projects has basically identified clinical candidate compounds. The project is far superior to the similar clinical compounds of several major international pharmaceutical companies in terms of in vitro inhibitory activity, selectivity, in vivo efficacy and toxicology. It is internationally advanced and is expected to have a higher safety level in clinic treatment. It has the potential to become a best-in-class drug and is expected to enter the clinical application stage.

Hyperway has now identified several candidate compounds in another innovative drug project, and they are significantly superior to the clinical drugs developed by other international pharmaceutical companies in terms of preclinical data such as inhibitory activity, selectivity, etc. Having reached an international leading level, these compounds are expected to have lower clinical doses and higher safety. The project is expected to quickly identify clinical candidate drugs and carry out the next round of research and development.

"Hyperway's greatest appeal is to have a team with a fighting spirit and strong implementation capacity. It has made the progress in less than 10 months which will take a vast majority of enterprises two to three years, so we think it has an unlimited potential for growth," said Dr. Du Jiangbo, a partner of Huaige Capital. During the outbreak of COVID-19, all the departments of Hyperway have realized rapid resumption of production through coordination. While other enterprises are still in their recovery stage, Hyperway has adjusted to open a new round of struggle!

About Huaige Capital

Huaige Capital is a private equity investment fund management company focusing on health care industry. It implements a two-wheel-drive investment strategy of "active investment + deep investment banking services " to actively seek potential investment areas, business models and good entrepreneurs. It also assists companies in designing strategic planning and operation mechanisms to obtain good equity prices and provide quality post-investment value-added services.  Its core team of fund management is composed of a number of professionals with senior investment banking background, innovative pharmaceutical and innovative medical device R&D background, and financial background. With its rich health care background and equity investment experience, the company mainly invests in drug research and development, medical devices, medical services and pharmaceutical outsourcing services. At present, Huaige Capital has successfully invested in a number of high-quality enterprises and projects, such as Kindly Medical Instruments, Cofoe, Ouwen Medical, Bestudy, BioSense, Leads Biolabs and Leto Laboratories.